Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Lymphoma 8Lymphoma, T-Cell, Cutaneous 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, T-Cell, Peripheral 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, Follicular 4Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Drug-Related Side Effects and Adverse Reactions 2Waldenstrom Macroglobulinemia 1Recurrence 1Neoplasms by Histologic Type 1Neoplasms 1Mastocytosis, Systemic 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphatic Diseases 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Mast-Cell 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 5Etoposide 4Cytarabine 3sargramostim 2denileukin diftitox 2Radiotherapy 2Filgrastim 2Dexamethasone 2Carboplatin 2Amifostine 2sodium thiosulfate 1pegfilgrastim 1pegaspargase 1glucarpidase 1etoposide phosphate 1Vincristine 1Silymarin 1Rituximab 1Prednisolone 1Phenobarbital 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Irinotecan 1Ifosfamide 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Fibroblast Growth Factor 7 1Epoetin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × denileukin diftitox × Lymphoid × Clear all
NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡